PDA Releases Technical Report on TBA and TCA Odors and Taints - - BioPharm International

ADVERTISEMENT

PDA Releases Technical Report on TBA and TCA Odors and Taints



The Parenteral Drug Association has released guidance on the detection and mitigation of 2,4,6-Tribromoanisole (TBA) and 2,4,6-Trichloroanisole (TCA) taints and odors in pharmaceutical and healthcare products.

Technical Report Number 55 (TR 55) provides information on the origin of TBA and TCA odors and taints, analytical methods developed, and risk management strategies. The report highlights the uses of 2,4,6-tribromophenol (TBP) and 2,4,6-trichlorophenol (TCP); the role of fungal halophenol methylation that generates TBA and TCA haloanisole taints; and sensory and physiochemical properties of TBP, TCP, TBA, and TCA. The report also gives case examples of recalls, the root causes behind those recalls, and remedial actions taken.

From 2009 to 2011, companies in the pharmaceutical and consumer healthcare industries experienced product recalls due to the risk of product exposure to the TBA taint from tribromophenol-treated wood pallets. TR 55 offers “guidance on signal detection from adverse event and/or product quality complaints and resulting recalls, toxicology and safety, analytical method development and use, supply chain controls, risk analysis and mitigation.”

PDA members can access TR 55 for free until May 31, 2012.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here